Floatz logo

5-ala

Lentigo Maligna

Joint Authority for Päijät-Häme Social and Health CareSmall moleculePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Lentigo Maligna cohort.

Asset / SponsorPhaseRating
Imiquimod
Melanoma and Skin Cancer Trials Limited
Phase 4BBB
INGENOL MEBUTATE
Centre Hospitalier Universitaire de Nice
Phase 2B
Cediranib
National Cancer Institute (NCI)
Phase 2B
Dinaciclib
National Cancer Institute (NCI)
Phase 2CCC
rg4733
National Cancer Institute (NCI)
Phase 2CC
Tazarotene
University of Utah
N/AD

Same molecule, other indications

5-ala is also rated in:

brain neoplasmDormant
B
Indicative ·
61 / 100
View asset →
glioblastomaDormant
B
Indicative ·
58 / 100
View asset →
brain neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →